- Featured Product
- KD/KO Validated
IDO1 Polyklonaler Antikörper
IDO1 Polyklonal Antikörper für WB, IHC, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human und mehr (3)
Anwendung
WB, IF, IHC, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 13268-1-AP
Synonyme
Galerie der Validierungsdaten
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | humanes Plazenta-Gewebe, mit IFN-gamma behandelte HeLa-Zellen |
Erfolgreiche Detektion in IHC | humanes Tonsillitisgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
Immunhistochemie (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
KD/KO | See 3 publications below |
WB | See 49 publications below |
IHC | See 11 publications below |
IF | See 8 publications below |
Produktinformation
13268-1-AP bindet in WB, IF, IHC, ELISA IDO1 und zeigt Reaktivität mit human
Getestete Reaktivität | human |
In Publikationen genannte Reaktivität | human, Hund, Maus, Ratte |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | IDO1 fusion protein Ag3953 |
Vollständiger Name | indoleamine 2,3-dioxygenase 1 |
Berechnetes Molekulargewicht | 403 aa, 45 kDa |
Beobachtetes Molekulargewicht | 42 kDa |
GenBank-Zugangsnummer | BC027882 |
Gene symbol | IDO1 |
Gene ID (NCBI) | 3620 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3. |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
IDO1 is the target for therapy in a range of clinical settings, including cancer, chronic infections, autoimmune and allergic syndromes, and transplantation. Elevated IDO1 expression is a hallmark of major viral infections including HIV, HBV, HCV or influenza and also of major bacteria infections, such as Tb, CAP, listeriosis and sepsis. Pathogens are able to highjack the immunosuppressive effects of IDO1 and make use of them to facilitate their own life cycle. MW of IDO1 is 40-42kd (PMID: 14502282; 17055065).
Protokolle
Produktspezifische Protokolle | |
---|---|
WB protocol for IDO1 antibody 13268-1-AP | Protokoll herunterladen |
IHC protocol for IDO1 antibody 13268-1-AP | Protokoll herunterladen |
Standard-Protokolle | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Hepatology Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.
| ||
Acta Biomater Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. | ||
ACS Appl Mater Interfaces Mitigation Effects of Selenium Nanoparticles on Depression-Like Behavior Induced by Fluoride in Mice via the JAK2-STAT3 Pathway. | ||
J Immunother Cancer GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer. | ||
J Immunother Cancer Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. | ||
Theranostics Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. |
Rezensionen
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH Christopher (Verified Customer) (01-28-2022) | Worked well with a 1 hour incubation at room temperature.
|
FH Hala (Verified Customer) (09-18-2020) | I am very satisfied of this antibody and of the interaction with your company
|